Ablynx Appoints CMO
This article was originally published in Scrip
Ablynx has appointed Robert K. Zeldin chief medical officer (CMO) – effective Dec. 1, 2015. Previously Zeldin held senior level clinical development positions at Merck & Co., Inc. and Novartis Pharmaceuticals Corp. Prior to his positions in the pharmaceutical industry, Zeldin spent several years in private practice and two years as medical officer at the FDA's centre for biologics evaluation and research.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.